Genzyme and Isis Announce Submission of U.S. NDA for KYNAMRO in Homozygous Familial Hypercholesterolemia
Genzyme, a Sanofi company (NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that Genzyme has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for KYNAMRO™ (mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.